{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-076222","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2024-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.773838+00:00","generated_at":"2026-06-01T02:49:22.966430+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Ultragenyx stockholders approve amended 2023 incentive plan and elect directors at annual meeting","bullets":["Class II directors Dunsire, Narachi, and Sanders elected with over 66M votes each for terms until 2027.","Amended 2023 Incentive Plan approved: 51.9M for, 22.3M against; adds 8.5M shares plus prior plan rollover shares.","Ernst & Young ratified as independent auditor for FY2024 with 77.2M votes for (98.2% of votes cast).","Advisory vote on executive compensation passed with 54.8M for vs 19.3M against; 4.3M broker non-votes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-076222","json":"https://secwatch.observer/filing/0000950170-24-076222.json","markdown":"https://secwatch.observer/filing/0000950170-24-076222.md","text":"https://secwatch.observer/filing/0000950170-24-076222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024076222/0000950170-24-076222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024076222/rare-20240618.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:49:22.966430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}